RCMI Coordinating Center (RCMI CC) Header Logo

Emmanuel O. Akala, PhD

TitleChair, Howard University Institutional Animal Care and Use Committee (IACUC)
Faculty RankProfessor
InstitutionHoward University
Address2400 Sixth St NW
Washington DC 20059
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21AA013407     (AKALA, EMMANUEL O)Feb 1, 2002 - Aug 31, 2006
    NIH
    Controlled Delivery System for Naltrexone
    Role: Principal Investigator
    SC2CA138179     (AKALA, EMMANUEL O)Jul 1, 2008 - Dec 31, 2012
    NIH
    Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
    Role: Principal Investigator
    SC1CA199810     (AKALA, EMMANUEL O)May 1, 2015 - Apr 30, 2019
    NIH
    Novel Nanotechnology Platform for Breast Cancer Treatment
    Role: Principal Investigator
    R16GM145483     (AKALA, EMMANUEL O)Aug 1, 2022 - Jun 30, 2026
    NIH
    Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Battogtokh G, Obidiro O, Akala EO. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC). Cancers (Basel). 2024 May 25; 16(11). PMID: 38893132.
      Citations:    
    2. Obidiro O, Battogtokh G, Akala EO. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. 2023 Jun 23; 15(7). PMID: 37513983.
      Citations:    
    3. Akala EO. Dispersion polymerization induced self-assembly (pisa) techniques for the fabrication of polymeric nanoparticles for biomedical applications. Nanotechnol Lett. 2023 Jan; 8(1):1-15. PMID: 39081630.
      Citations:    
    4. Ejigah V, Mandala B, Akala EO. Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer. J Cancer Metastasis Res. 2022; 4(2):6-22. PMID: 38966076.
      Citations:    
    5. Wu B, Chen Y, Clarke R, Akala E, Yang P, He B, Gao H. AMPK Signaling Regulates Mitophagy and Mitochondrial ATP Production in Human Trophoblast Cell Line BeWo. Front Biosci (Landmark Ed). 2022 04 01; 27(4):118. PMID: 35468677.
      Citations: 3     Fields:    Translation:HumansCells
    6. Awuonda MK, Akala E, Wingate LT, Weaver SB, Brown K, Williams-Fowlkes C, Tofade T. A Pre-matriculation Success Program to Improve Pharmacy Students' Academic Performance at a Historically Black University. Am J Pharm Educ. 2021 06; 85(6):8214. PMID: 34315700.
      Citations: 1     Fields:    Translation:Humans
    7. Fisusi F, Brandy N, Wu J, Akala EO. Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications. J Nanosci Nanomed. 2020 Jul; 4(2):1-9. PMID: 33564752.
      Citations:    
    8. Berko YA, Akala EO. Computer Optimization of Stealth Biodegradable Polymeric Dual-loaded Nanoparticles for Cancer Therapy Using Central Composite Face-centered Design. Pharm Nanotechnol. 2020; 8(2):108-132. PMID: 32091350.
      Citations: 2     Fields:    Translation:Cells
    9. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019; 7(1):3-23. PMID: 30666921.
      Citations: 124     Fields:    Translation:Humans
    10. Puri R, Adesina S, Akala E. Cellular uptake and cytotoxicity studies of pH-responsive polymeric nanoparticles fabricated by dispersion polymerization. J Nanosci Nanomed. 2018 Sep; 2(1):3-18. PMID: 34263267.
      Citations:    
    11. Puri R, Berhe SA, Akala EO. pH-Sensitive Polymeric Nanoparticles Fabricated by Dispersion Polymerization for the Delivery of Bioactive Agents. Pharm Nanotechnol. 2017; 5(1):44-66. PMID: 28948910.
      Citations: 6     Fields:    Translation:HumansCells
    12. Ogunwuyi O, Kumari N, Smith KA, Bolshakov O, Adesina S, Gugssa A, Anderson WA, Nekhai S, Akala EO. Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment. Infect Dis (Auckl). 2016; 9:21-32. PMID: 27013886.
      Citations:    
    13. Akala EO, Adesina S, Ogunwuyi O. Computer Optimization of Biodegradable Nanoparticles Fabricated by Dispersion Polymerization. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010047. PMID: 26703678.
      Citations: 5     Fields:    Translation:Cells
    14. Adesina SK, Akala EO. Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy. Mol Pharm. 2015 Dec 07; 12(12):4175-87. PMID: 26524196.
      Citations: 25     Fields:    Translation:HumansAnimals
    15. Smith KA, Lin X, Bolshakov O, Griffin J, Niu X, Kovalskyy D, Ivanov A, Jerebtsova M, Taylor RE, Akala E, Nekhai S. Activation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein Phosphatase-1-Targeting Compound. Sci Pharm. 2015 Jul-Sep; 83(3):535-48. PMID: 26839837.
      Citations:    
    16. Bol'shakov OI, Akala EO. MS-Monitored Conjugation of Poly(ethylene glycol) Monomethacrylate to RGD Peptides. J Appl Polym Sci Symp. 2014 Jul 15; 131(14). PMID: 24976670.
      Citations:    
    17. Adesina SK, Holly A, Kramer-Marek G, Capala J, Akala EO. Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J Pharm Sci. 2014 Aug; 103(8):2546-55. PMID: 24961596.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    18. Adesina SK, Wight SA, Akala EO. Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design. Drug Dev Ind Pharm. 2014 Nov; 40(11):1547-56. PMID: 24059281.
      Citations: 11     Fields:    
    19. Akala EO, Wiriyacoonkasem P, Pan G. Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres. Drug Dev Ind Pharm. 2011 Jun; 37(6):673-84. PMID: 21449706.
      Citations: 9     Fields:    
    20. Akala EO, Wang H, Adedoyin A. Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. Neuropsychobiology. 2008; 58(2):81-90. PMID: 18832863.
      Citations: 5     Fields:    Translation:Animals
    21. Akala EO, Elekwachi O, Chase V, Johnson H, Lazarre M, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev Ind Pharm. 2003 Apr; 29(4):375-86. PMID: 12737531.
      Citations: 8     Fields:    Translation:Cells
    22. Yin W, Akala EO, Taylor RE. Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. Int J Pharm. 2002 Sep 05; 244(1-2):9-19. PMID: 12204561.
      Citations: 12     Fields:    
    Akala's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (82)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support